{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:16:06Z","timestamp":1779297366849,"version":"3.51.4"},"reference-count":125,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.<\/jats:p>","DOI":"10.3390\/cancers13215435","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:47:38Z","timestamp":1635767258000},"page":"5435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells"],"prefix":"10.3390","volume":"13","author":[{"given":"Maiko","family":"Matsushita","sequence":"first","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the BELA Trial","volume":"30","author":"Kim","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic my-elogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"643382","DOI":"10.3389\/fonc.2021.643382","article-title":"Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation","volume":"11","author":"Mu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: Who, how, and why?","volume":"1","author":"Mahon","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kwa\u015bnik, P., and Giannopoulos, K. (2021). Treatment-Free Remission\u2014A New Aim in the Treatment of Chronic Myeloid Leukemia. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080697"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1038\/bcj.2017.84","article-title":"CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients","volume":"7","author":"Matsushita","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35293","DOI":"10.18632\/oncotarget.9182","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation","volume":"7","author":"Chomel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematol."},{"key":"ref_18","first-page":"2935","article-title":"Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib","volume":"15","author":"Jo","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoiddendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Inselmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/bjh.16506","article-title":"Prospects for achieving treatment-free remission in chronic myeloid leukaemia","volume":"190","author":"Saglio","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","article-title":"BCR-ABL\u2013Induced Deregulation of the IL-33\/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients","volume":"74","author":"Levescot","year":"2014","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","article-title":"Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration","volume":"101","author":"Dong","year":"2003","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood.V96.5.1961","article-title":"Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: Role of reactive oxygen species and regulation by histamine","volume":"96","author":"Mellqvist","year":"2000","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR\u2013ABL-positive mice","volume":"26","author":"Chen","year":"2011","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Blom","year":"2018","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/10428194.2019.1658098","article-title":"The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia","volume":"61","author":"Xu","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","article-title":"Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate","volume":"153","author":"Bachy","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbmt.2017.10.039","article-title":"Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study","volume":"24","author":"Costantini","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20191009","DOI":"10.1084\/jem.20191009","article-title":"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells","volume":"217","author":"Tanaka","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1638210","DOI":"10.1080\/2162402X.2019.1638210","article-title":"Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line","volume":"8","author":"Kreutzman","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia","volume":"9","author":"Chang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","article-title":"Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response\u2014The final results of the D-first study","volume":"66","author":"Najima","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.14692","article-title":"Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment","volume":"112","author":"Ishiyama","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"300060519877321","DOI":"10.1177\/0300060519877321","article-title":"Effects of dasatinib on CD8+T, Th1, and Treg cells in patients with chronic myeloid leukemia","volume":"48","author":"Wei","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-9-22","article-title":"Effects of nilotinib on regulatory T cells: The dose matters","volume":"9","author":"Fei","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-018-2129-9","article-title":"The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells","volume":"67","author":"Lechner","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.2020005655","article-title":"Concomitant use of a dual Src\/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL","volume":"137","author":"Leonard","year":"2021","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11899-019-00548-2","article-title":"Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice","volume":"14","author":"Clark","year":"2019","journal-title":"Curr. Hematol. Malign Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0642-1","article-title":"Treatment-Free Remission: A New Therapeutic Goal in Chronic Myelogenous Leukemia","volume":"19","author":"Elsayed","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2011","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bdq.2017.01.001","article-title":"Molecular techniques for the personalised management of patients with chronic myeloid leukaemia","volume":"11","author":"Alikian","year":"2017","journal-title":"Biomol. Detect. Quantif."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/cam4.2087","article-title":"Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation","volume":"8","author":"Bernardi","year":"2019","journal-title":"Cancer Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15858","article-title":"Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1002\/cam4.2371","article-title":"Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission","volume":"8","author":"Dumas","year":"2019","journal-title":"Cancer Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"Caocci","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","article-title":"The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era","volume":"26","author":"Schmidt","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/bmt.2009.177","article-title":"Outcome of patients developing GVHD after DLI given to treat CML relapse: A study by the Chronic Leukemia Working Party of the EBMT","volume":"45","author":"Chalandon","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Italian Cooperative Study Group on Chronic Myeloid Leukemia, Tura, S., Baccarani, M., Zuffa, E., Russo, D., Fanin, R., Zaccaria, A., and Fiacchini, M. (1994). Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med., 330, 820\u2013825.","DOI":"10.1056\/NEJM199403243301204"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/jir.2012.0117","article-title":"Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy","volume":"33","author":"Fuchs","year":"2013","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V89.3.957","article-title":"Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia","volume":"89","author":"Selleri","year":"1997","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kwaa, A.K.R., Talana, C.A.G., and Blankson, J.N. (2019). Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8 + T Cells. J. Virol., 93.","DOI":"10.1128\/JVI.01541-18"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2402602","article-title":"Interferon-\u03b1 induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo","volume":"16","author":"Paquette","year":"2002","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4049\/jimmunol.142.1.297","article-title":"IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes","volume":"142","author":"Hakem","year":"1989","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Polivkova, V., Rohon, P., Klamova, H., Cerna, O., Divoka, M., Curik, N., Zach, J., Novak, M., Marinov, I., and Soverini, S. (2016). Interferon-\u03b1 Revisited:Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS ONE., 11.","DOI":"10.1371\/journal.pone.0155959"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus pegylated interferon-alpha2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","article-title":"Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: Results from the French SPIRIT phase III randomised trial","volume":"35","author":"Guilhot","year":"2021","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2014006","DOI":"10.4084\/mjhid.2014.006","article-title":"Tyrosine kinase inhibitors and interferon","volume":"6","author":"Dimou","year":"2014","journal-title":"Mediterr J. Hematol. Infect Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Stentoft","year":"2016","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Flygt, H., S\u00f6derlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., L\u00fcbking, A., Dreimane, A., and Markev\u00e4rn, B. (2021). Long-term tolerability and efficacy after initial PegIFN-\u03b1 addition to dasatinib in CML-CP - five-year follow-up of the NordCML007 study. Eur. J. Haematol.","DOI":"10.1111\/ejh.13699"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and pegylated interferon alfa 2a for newly diagnosed chronic phase chronic myeloid leukaemia patients. Results of amulticentric phase II study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2174\/15680096113139990086","article-title":"Advances in Immunotherapy of Chronic Myeloid Leukemia CML","volume":"13","author":"Held","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428194.2020.1762884","article-title":"Wilms\u2019 tumor 1 gene in hematopoietic malignancies: Clinical implications and future directions","volume":"61","author":"Luo","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1182\/blood-2010-09-308569","article-title":"Prophylactic transfer of BCR-ABL\u2013, PR1-, and WT1-reactive donor T cells after T cell\u2013depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia","volume":"117","author":"Thiede","year":"2011","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1046\/j.1365-2141.2001.02670.x","article-title":"Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia","volume":"112","author":"Matsushita","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T ly mphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood.V85.10.2680.bloodjournal85102680","article-title":"Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules","volume":"85","author":"Bocchia","year":"1995","journal-title":"Blood"},{"key":"ref_93","first-page":"1324","article-title":"Synthetic peptide analogs derived from bcr\/abl fusion proteins and the induction of heteroclitic human T-cell responses","volume":"90","author":"Korontsvit","year":"2005","journal-title":"Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: A phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1568009023334088","article-title":"WT1 as a Novel Target Antigen for Cancer Immunotherapy","volume":"2","author":"Oka","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2010.01497.x","article-title":"WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient","volume":"85","author":"Oji","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity withAR-T clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2017.03.004","article-title":"Dendritic Cell Therapies for Hematologic Malignancies","volume":"5","author":"Weinstock","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4161\/onci.20954","article-title":"Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients","volume":"1","author":"Brusic","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in Non\u2013Small Cell Lung Cancer: Facts and Hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.33056","article-title":"Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors","volume":"147","author":"Tolba","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: Challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","article-title":"Mutational landscape of chronic myeloid leukemia: More than a single oncogene leukemia","volume":"62","author":"Kankainen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cell.2017.12.002","article-title":"CD19 CAR T Cells","volume":"171","author":"Sadelain","year":"2017","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients with and without Extramedullary Disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_114","first-page":"4787","article-title":"IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor\u2013Engineered T Cells","volume":"79","author":"Warda","year":"2018","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-020-0824-y","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor\u2013treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Javidi-Sharifi, N., and Hobbs, G. (2021). Future Directions in Chronic Phase CML Treatment. Curr. Hematol. Malign Rep., 1\u20139.","DOI":"10.1007\/s11899-021-00658-w"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bonemarrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Gof","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"ref_124","first-page":"380","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-14332-x","article-title":"Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:53Z","timestamp":1760167373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":125,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215435"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215435","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}